Traded May 13 – May 14, 2025 · largest single transaction ~$36K
Show all 2 transactions
May 14, 2025~$14K · 7,730 sh @ $1.86
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
APUS · NYSE · Pharmaceutical Preparations
Apimeds Pharmaceuticals US (APUS) · oqro.io/stocks/APUS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.60−0.14 (−8.05%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Apimeds Pharmaceuticals US was filed in the last 90 days. The latest on record was on May 15, 2025.
Since 2025, Apimeds Pharmaceuticals US insiders reported 4 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2025.
No open-market sale by an insider of Apimeds Pharmaceuticals US (APUS) was filed with the SEC in the last 90 days.
No trade in Apimeds Pharmaceuticals US (APUS) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−93.3% (−$22.40) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $24.00 on Nov 20, 2025 to $1.60 on Nov 20, 2026 (−93.3%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Matawan, Nj.
Last 12 months
−93.3%
Market value
$2.94M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 32K shares sold short (1.7% of shares outstanding), −56.4% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$2.9M
Free cash flow, last 12 months
−$11.8M
This quarter −$219K, a year earlier −$1.75M
Net debt
—
Debt —, cash $18K, at Sep 30, 2026
Net income, last 12 months
−$22.7M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Traded May 13 – May 14, 2025 · largest single transaction ~$36K
May 14, 2025~$14K · 7,730 sh @ $1.86
May 13, 2025~$36K · 20K sh @ $1.82
DetailsOfficial recordInsider buying
Traded May 12, 2025 · filed 2 days later
A major shareholder of Apimeds Pharmaceuticals US paid $2M out of pocket for Apimeds Pharmaceuticals US shares. 2 other people at Apimeds Pharmaceuticals US bought some too, in the same month. Shares held went up 34% with this purchase.
Insider buying
Traded May 12, 2025 · filed 2 days later
An Apimeds Pharmaceuticals US director paid $57K out of pocket for Apimeds Pharmaceuticals US shares. 2 other people at Apimeds Pharmaceuticals US bought some too, in the same month.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Top officer leaving
“Resignation of Interim Chief Financial Officer On September 29, 2026, Erick Frim notified Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), of his resignation as Interim Chief Financial Officer of the Company, effective immediately.”
8-K on sec.govSaid its annual or quarterly report would be late
“Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company ") has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the " Form 10-Q ") by the prescribed due date because the Company is in the process of finalizing the financial statements for the fiscal quarter ended March 31, 2026, and will need ad”
NT 10-Q on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govSaid its annual or quarterly report would be late
“Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company ") has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fourth quarter and fiscal year ended December 31, 2025 (the " 2025 Form 10-K ") by the prescribed due date because the Company is in the process of preparing the financial statements for the fourth quarter and fiscal year en”
NT 10-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Apimeds Pharmaceuticals US reported 4 open-market purchases and 0 sales since 2025; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $2.11M4×4 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
No Schedule 13D or 13G filing on APUS over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Latest annual report filed May 4, 2026. Read the filing
The risk factor headings of this report could not be read with confidence, so none are shown. They are in the filing.
From time to time, we may be involved in legal proceedings, claims, or regulatory matters arising in the ordinary course of business. As of the date of this Annual Report, we are not a party to any material pending legal proceedings, nor are we aware of any such proceedings contemplated by governmental authorities.
Source: SEC EDGAR, Form 10-K filed May 4, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Contracts, lobbying and filings
Company reports, price and press
Deals
Things to keep in mind
Fails to deliver: 236K shares (about $1.08M) were not delivered on time for settlement on Oct 6, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 60.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (3.1% on ATS, 57.4% with other brokers), close to its 12-week average of 59.9%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (16.3%), IBKR ATS (13.3%), INTELLIGENT CROSS LLC (12.5%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 16, 2026. Quarterly reports are not audited. Read the filing
No figure for the same quarter a year earlier
No figure for the same quarter a year earlier
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 3,000 words.
Apimeds Pharmaceuticals US, Inc. (“APUS,” the “Company,” “we,” “us,” or “our”) is a development-stage biopharmaceutical company incorporated in the State of Delaware. Our primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of acute pain and inflammation associated with knee osteoarthritis. We operate our biopharmaceutical business through our wholly owned subsidiary, Lokahi Therapeutics Inc. (“Lokahi”). Fiscal year 2025 was a transformative year for the Company. In addition to advancing our biopharmaceutical pipeline and completing our initial public offering on the New York Stock Exchange on May 12, 2025, we completed a merger with MindWave Innovations Inc. (“MindWave”) on December 1, 2025.
And 1 more heading in the filing.
Source: SEC EDGAR, Form 10-K filed May 4, 2026 and Form 10-Q filed Nov 16, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.